Lars Frelin

Om mig
Publikationer
Forskningsbidrag
CV
Populärvetenskap och samverkan

Om mig

Lars Frelin är docent, grundutbildningsansvarig (GUA) och föreståndare vid
Karolinska Institutet där han hängivet arbetar med forskning och utbildning
Lars mottog sin doktorsexamen från Karolinska Institutet år 2004. År 2013
blev han docent inom virologi. Under åren 2016-2023 var Lars programdirektor
och ansvararde för biomedicinska analytikerprogrammet, magisterprogrammet i
diagnostisk cytologi och magisterprogrammet i biomedicinsk
laboratorievetenskap. I början av 2020 blev han föreståndare för ANA
Futura. Lars är sedan 2023 grundutbildningsansvarig (GUA) och har
övergripande ansvar och beslutsbefogenheter för utbildningsfrågor på
grundnivå och avancerad nivå vid institutionen för laboratoriemedicin.
*Docent i virologi, Karolinska Institutet (2013-)
*Grundutbildningsansvarig (GUA) Labmed (2023-)
*Programdirektor för biomedicinska analytikerprogrammet och
magsiterprogrammet diagnostisk cytologi, Karolinska Institutet (2016-2023)
*Föreståndare ANA Futura, Karolinska Institutet (2020-)
*Medlem i Karolinska Institutets infrastrukturråd (2016-2019, 2019-2022,
2023-)

Forskningsbeskrivning

Tillsammans med medlemmarna i forskargruppen "Vaccin och immunterapi mot
virus och cancer (VIVAC)" fokuserar han på utveckling av vaccin mot
infektionssjukdomar.

Artiklar

Article: GASTROENTEROLOGY. 2024;167(3):522-537
Phosphatidylinositol 4-Kinase III Alpha Governs Cytoskeletal Organization for Invasiveness of Liver Cancer Cells
Tran CS; Kersten J; Yan J; Breinig M; Huth T; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlen G; Frelin L; Kuehnel F; Vondran FWR; Breuhahn K; Meuleman P; Heikenwaelder M; Schirmacher P; Bartenschlager R; Laketa V; Roessler S; Tschaharganeh DF; Saellberg M; Lohmann V
Article: MOLECULAR THERAPY. 2024;32(2):540-555
Distinct roles of vaccine-induced SARS-CoV-2-specific neutralizing antibodies and T cells in protection and disease
Yan J; Bangalore CR; Nikouyan N; Appelberg S; Silva DN; Yao H; Pasetto A; Weber F; Weber S; Larsson O; Hoglund U; Bogdanovic G; Grabbe M; Aleman S; Szekely L; Szakos A; Tuvesson O; Gidlund E-K; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; Mirazimi A; Ahlen G; Sallberg M
Article: GUT. 2023;72(6):1186-1195
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
Burm R; Maravelia P; Ahlen G; Ciesek S; Perez NC; Pasetto A; Urban S; Van Houtte F; Verhoye L; Wedemeyer H; Johansson M; Frelin L; Sallberg M; Meuleman P
Journal article: JOURNAL OF HEPATOLOGY. 2023;78:s1038
FRI-252 Prophylactic vaccine against hepatitis D virus (HDV) superinfection
Sällberg M; Frelin L; Ahlén G; Yan J; Maravelia P; Cunnah P; Ricardo A-R; Mertens N; Bethell R
Article: EMBO MOLECULAR MEDICINE. 2022;14(10):e15821
A universal SARS-CoV DNA vaccine inducing highly cross-reactive neutralizing antibodies and T cells
Appelberg S; Ahlen G; Yan J; Nikouyan N; Weber S; Larsson O; Hoglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Salati S; Cadossi M; Tegel H; Hober S; Frelin L; Mirazimi A; Sallberg M
Journal article: JOURNAL OF HEPATOLOGY. 2022;77:s860
SAT413 Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection
Frelin L; Maravelia P; Burm R; Ni Y; Ahlén G; Verhoye L; Van Houtte F; Pasetto A; Urban S; Meuleman P; Sällberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 2021;223(1):128-138
Blocking Entry of Hepatitis B and D Viruses to Hepatocytes as a Novel Immunotherapy for Treating Chronic Infections
Maravelia P; Frelin L; Ni Y; Perez NC; Ahlen G; Jagya N; Verch G; Verhoye L; Pater L; Johansson M; Pasetto A; Meuleman P; Urban S; Sallberg M
Article: CLINICAL & TRANSLATIONAL IMMUNOLOGY. 2021;10(7):e1306
SARS-CoV-2-specific humoral and cellular immunity persists through 9 months irrespective of COVID-19 severity at hospitalisation
Sandberg JT; Varnaite R; Christ W; Chen P; Muvva JR; Maleki KT; Garcia M; Dzidic M; Folkesson E; Skagerberg M; Ahlen G; Frelin L; Sallberg M; Eriksson LI; Rooyackers O; Sonnerborg A; Buggert M; Bjorkstrom NK; Aleman S; Stralin K; Klingstrom J; Ljunggren H-G; Blom K; Gredmark-Russ S
Article: JOURNAL OF IMMUNOLOGY. 2020;205(9):2437-2446
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Varnaite R; Garcia M; Glans H; Maleki KT; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlen G; Frelin L; Sallberg M; Blom K; Klingstrom J; Gredmark-Russ S
Article: HUMAN VACCINES & IMMUNOTHERAPEUTICS. 2020;16(2):251-268
Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance
Whitacre DC; Peters CJ; Sureau C; Nio K; Li F; Su L; Jones JE; Isogawa M; Sallberg M; Frelin L; Peterson DL; Milich DR
Article: GUT. 2018;67(8):1525-1535
Immune-mediated effects targeting hepatitis C virus in a syngeneic replicon cell transplantation mouse model
Levander S; Holmstrom F; Frelin L; Ahlen G; Rupp D; Long G; Bartenschlager R; Sallberg M
Journal article: JOURNAL OF HEPATOLOGY. 2018;68:s307
THU-394 Full analysis of comorbidities in chronic hepatitis Cpatients compared with matched comparators: A nationwide population-based register study from 2001 to 2013
Söderholm J; Buesch K; Frelin L; Brolund A; Kövamees J; Sällberg M; Lagging M
Article: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2018;66(1):106-111
Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers
Einberg AP; Brenndorfer ED; Frelin L; Hallberg L; Sallberg M; Fischler B
Article: JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION. 2017;65(6):608-612
Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C
Einberg AP; Duberg A-S; Filipovich O; Nystrom J; Zhirkov A; Brenndorfer ED; Frelin L; Rukoiatkina E; Lobzin Y; Sallberg M; Fischler B; Lutckii A
Article: JOURNAL OF VIROLOGY. 2017;91(9):e00010-e00017
Hepatitis C Virus-Specific T Cell Receptor mRNA-Engineered Human T Cells: Impact of Antigen Specificity on Functional Properties
Balasiddaiah A; Davanian H; Aleman S; Pasetto A; Frelin L; Sallberg M; Lohmann V; Koh S; Bertoletti A; Chen M
Article: VACCINE. 2016;34(25):2821-2833
A non-human hepadnaviral adjuvant for hepatitis C virus-based genetic vaccines
Levander S; Sallberg M; Ahlen G; Frelin L
Article: SCIENTIFIC REPORTS. 2016;6:24991
Functional differences in hepatitis C virus nonstructural (NS) 3/4A-and 5A-specific T cell responses
Holmstrom F; Chen M; Balasiddaiah A; Sallberg M; Ahlen G; Frelin L
Article: METHODS IN MOLECULAR BIOLOGY. 2016;1403:221-244
Methods to Evaluate Novel Hepatitis C Virus Vaccines.
Ahlén G; Frelin L
Article: MOLECULAR THERAPY: METHODS & CLINICAL DEVELOPMENT. 2016;3:16016
A targeted controlled force injection of genetic material in vivo
Ahlen G; Frelin L; Holmstrom F; Smetham G; Augustyn S; Sallberg M
Article: MOLECULAR THERAPY. 2015;23(3):578-590
Functional Aspects of Intrahepatic Hepatitis B Virus-specific T Cells Induced by Therapeutic DNA Vaccination
Brass A; Frelin L; Milich DR; Saellberg M; Ahlen G
Article: PLOS ONE. 2015;10(6):e0128466
Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo
Bansal R; Frelin L; Brenndorfer ED; Storm G; Prakash J; Sallberg M
Article: GENE THERAPY. 2014;21(8):739-750
Long-term functional duration of immune responses to HCV NS3/4A induced by DNA vaccination
Ahlen G; Holmstrom F; Gibbs A; Alheim M; Frelin L
Article: JOURNAL OF INFECTIOUS DISEASES. 2013;208(6):1008-1019
A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus
Fournillier A; Frelin L; Jacquier E; Ahlen G; Brass A; Gerossier E; Holmstrom F; Broderick KE; Sardesai NY; Bonnefoy J-Y; Inchauspe G; Sallberg M
Article: MOLECULAR THERAPY. 2013;21(9):1796-1805
Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
Weiland O; Ahlen G; Diepolder H; Jung M-C; Levander S; Fons M; Mathiesen I; Sardesai NY; Vahlne A; Frelin L; Sallberg M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2013;433(1):31-35
Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients
Rahbin N; Frelin L; Aleman S; Hultcrantz R; Sallberg M; Brenndorfer ED
Article: JOURNAL OF IMMUNOLOGY. 2013;190(3):1113-1124
A Synthetic Codon-Optimized Hepatitis C Virus Nonstructural 5A DNA Vaccine Primes Polyfunctional CD8⁺ T Cell Responses in Wild-Type and NS5A-Transgenic Mice
Holmstrom F; Pasetto A; Nahr V; Brass A; Kriegs M; Hildt E; Broderick KE; Chen M; Ahlen G; Frelin L
Article: METHODS IN MOLECULAR BIOLOGY. 2013;940:239-267
Methods for monitoring gene gun-induced HBV- and HCV-specific immune responses in mouse models.
Ahlén G; Sällberg M; Frelin L
Article: JOURNAL OF IMMUNOLOGY. 2012;189(9):4510-4519
TCR-Redirected Human T Cells Inhibit Hepatitis C Virus Replication: Hepatotoxic Potential Is Linked to Antigen Specificity and Functional Avidity
Pasetto A; Frelin L; Aleman S; Holmstrom F; Brass A; Ahlen G; Brenndorfer ED; Lohmann V; Bartenschlager R; Sallberg M; Bertoletti A; Chen M
Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 8):1680-1686
Limited effect on NS3-NS4A protein cleavage after alanine substitutions within the immunodominant HLA-A2-restricted epitope of the hepatitis C virus genotype 3a non-structural 3/4A protease
Ahlen G; Chen A; Roe B; Falkeborn T; Frelin L; Hall WW; Sallberg M; Soderholm J
Article: GUT. 2012;61(4):589-596
Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production
Brenndorfer ED; Brass A; Soderholm J; Frelin L; Aleman S; Bode JG; Sallberg M
Article: JOURNAL OF GENERAL VIROLOGY. 2012;93(Pt 2):247-258
Generation of T-cell receptors targeting a genetically stable and immunodominant cytotoxic T-lymphocyte epitope within hepatitis C virus non-structural protein 3
Pasetto A; Frelin L; Brass A; Yasmeen A; Koh S; Lohmann V; Bartenschlager R; Magalhaes I; Maeurer M; Sallberg M; Chen M
Article: SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES. 2012;44(1):55-59
A bi-functional hepatitis B virus core antigen (HBcAg) chimera activates HBcAg-specific T cells and preS1-specific antibodies
Malik IR; Chen A; Brass A; Ahlen G; Rahman M; Sallberg M; Qureshi JA; Frelin L
Journal article: IMMUNOLOGY. 2011;134(4):434-447
Identification of a unique double-negative regulatory T-cell population
Lee BO; Jones JE; Peters CJ; Whitacre D; Frelin L; Hughes J; Kim W-K; Milich DR
Article: APMIS. 2011;119(7):412-420
Microvesicular fat, inter cellular adhesion molecule-1 and regulatory T-lymphocytes are of importance for the inflammatory process in livers with non-alcoholic steatohepatitis
Soderberg C; Marmur J; Eckes K; Glaumann H; Sallberg M; Frelin L; Rosenberg P; Stal P; Hultcrantz R
Article: JOURNAL OF IMMUNOLOGY. 2011;186(9):5107-5118
Heterologous T Cells Can Help Restore Function in Dysfunctional Hepatitis C Virus Nonstructural 3/4A-Specific T Cells during Therapeutic Vaccination
Chen A; Ahlen G; Brenndorfer ED; Brass A; Holmstrom F; Chen M; Soderholm J; Milich DR; Frelin L; Sallberg M
Article: DRUG NEWS AND PERSPECTIVES. 2010;23(10):647-653
ELECTROPORATION: A PROMISING METHOD FOR THE NONVIRAL DELIVERY OF DNA VACCINES IN HUMANS?
Frelin L; Brass A; Ahlen G; Brenndorfer ED; Chen M; Sallberg M
Article: HEPATOLOGY. 2010;52(5):1553-1563
Anti-Tumor Necrosis Factor α Treatment Promotes Apoptosis and Prevents Liver Regeneration in a Transgenic Mouse Model of Chronic Hepatitis C
Brenndorfer ED; Weiland M; Frelin L; Derk E; Ahlen G; Jiao J; Bode JG; Sallberg M
Article: JOURNAL OF INFECTIOUS DISEASES. 2010;201(12):1867-1879
Improving on the Ability of Endogenous Hepatitis B Core Antigen to Prime Cytotoxic T Lymphocytes
Nystrom J; Chen A; Frelin L; Ahlen G; Koh S; Brass A; Peterson DL; Fons M; Milich DR; Hultgren C; Sallberg M
Journal article: JOURNAL OF HEPATOLOGY. 2010;52:s265
680 HCV NS3/4A INTERFERES WITH INTRAHEPATIC IMMUNITY AND TNFA-INDUCED LIVER DAMAGE BY MODULATING CCL17 AND CXCL9 SECRETION IN VIVO
Brenndörfer ED; Frelin L; Söderholm J; Bode JG; Sällberg M
Journal article: JOURNAL OF HEPATOLOGY. 2010;52:s265
681 HCV NS3/4A-MEDIATED CCL2 AND TNFA SECRETION INCREASE HEPATOCYTE SURVIVAL AND LIVER REGENERATION IN VIVO
Brenndörfer ED; Weiland M; Frelin L; Derk E; Ahlen G; Bode JG; Sällberg M
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2009;284(41):28343-28351
The Hepatitis C Virus Non-structural NS5A Protein Impairs Both the Innate and Adaptive Hepatic Immune Response in Vivo
Kriegs M; Buerckstuemmer T; Himmelsbach K; Bruns M; Frelin L; Ahlen G; Sallberg M; Hildt E
Article: JOURNAL OF IMMUNOLOGY. 2009;182(11):6670-6681
Interaction of the Hepatitis B Core Antigen and the Innate Immune System
Lee BO; Tucker A; Frelin L; Sallberg M; Jones J; Peters C; Hughes J; Whitacre D; Darsow B; Peterson DL; Milich DR
Article: HEPATOLOGY. 2009;49(6):1810-1820
Nonstructural 3/4A Protease of Hepatitis C Virus Activates Epithelial Growth Factor-Induced Signal Transduction by Cleavage of the T-Cell Protein Tyrosine Phosphatase
Brenndorfer ED; Karthe J; Freblin L; Cebula P; Erhardt A; Esch JSA; Hengel H; Bartenschlager R; Sallberg M; Haussinger D; Bode JG
Article: GUT. 2009;58(4):560-569
Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes
Ahlen G; Derk E; Weiland M; Jiao J; Rahbin N; Aleman S; Peterson DL; Pokrovskaja K; Grander D; Frelin L; Sallberg M
Journal article: JOURNAL OF VIROLOGY. 2009;83(3):1379-1392
A Mechanism To Explain the Selection of the Hepatitis e Antigen-Negative Mutant during Chronic Hepatitis B Virus Infection
Frelin L; Wahlstroem T; Tucker AE; Jones J; Hughes J; Lee BO; Billaud J-N; Peters C; Whitacre D; Peterson D; Milich DR
Journal article: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2009;47(01)
The hepatitis C virus non-structural 3/4A protease activates Akt-dependent host cell signaling which is required for sufficient viral replication
Brenndörfer E; Karthe J; Cebula P; Erhardt A; Frelin L; Schulte am Esch J; Häussinger D; Bode J; Sällberg M
Journal article: DRUG DISCOVERY TODAY: THERAPEUTIC STRATEGIES. 2007;4(4):253-266
Therapeutic vaccines: challenges of chronic viral infections
Sällberg M; Weiland M; Frelin L
Article: JOURNAL OF IMMUNOLOGY. 2007;179(7):4741-4753
In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3⁺ T cells
Ahlen G; Soderholm J; Tjelle T; Kjeken R; Frelin L; Hoglund U; Blomberg P; Fons M; Mathiesen I; Sallberg M
Article: GUT. 2006;55(10):1475-1483
The hepatitis C virus and immune evasion:: nonstructural 3/4A transgenic mice are resistant to lethal tumour necrosis factor α mediated liver disease
Frelin L; Brenndorfer ED; Ahlen G; Weiland M; Hultgren C; Alheim M; Glaumann H; Rozell B; Milich DR; Bode JG; Sallberg M
Article: GUT. 2006;55(2):266-274
Relation between viral fitness and immune escape within the hepatitis C virus protease
Söderholm J; Ahlén G; Kaul A; Frelin L; Alheim M; Barnfield C; Liljeström P; Weiland O; Milich DR; Bartenschlager R; Sällberg M
Journal article: ZEITSCHRIFT FUR GASTROENTEROLOGIE. 2006;44(01)
Modifikation TNF-alpha induzierter Signalvermittlung durch das NS3/4A-Protein des Hepatitis C Virus in NS3/4A transgenen Mäusen
Brenndörfer E; Frelin L; Alheim M; Hultgren C; Ahlen G; Häussinger D; Sällberg M; Bode J
Article: JOURNAL OF INFECTIOUS DISEASES. 2005;192(12):2112-2116
In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes
Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sällberg M
Article: GENE THERAPY. 2004;11(6):522-533
Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene
Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
Article: GENE THERAPY. 2003;10(8):686-699
Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo
Frelin L; Alheim M; Chen A; Söderholm J; Rozell B; Barnfield C; Liljeström P; Sällberg M
Article: JOURNAL OF GENERAL VIROLOGY. 2001;82(Pt 6):1299-1308
Humoral and CD4⁺ T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein:: NS3 primes Th 1-like responses more effectively as a DNA-based immunogen than as a recombinant protein
Lazdina U; Hultgren C; Frelin L; Chen M; Lodin K; Weiland O; Leroux-Roels G; Quiroga JA; Peterson DL; Milich DR; Sällberg M
Visa fler

Alla övriga publikationer

Preprint: BIORXIV. 2023
Phosphatidylinositol 4-kinase III alpha governs cytoskeletal organization for invasiveness of liver cancer cells
Tran CS; Kersten J; Breinig M; Yan J; Poth T; Colasanti O; Riedl T; Faure-Dupuy S; Diehl S; Verhoye L; Li T-F; Lingemann M; Schult P; Ahlén G; Frelin L; Kühnel F; Breuhahn K; Vondran FWR; Meuleman P; Heikenwälder M; Schirmacher P; Sällberg M; Bartenschlager R; Laketa V; Tschaharganeh DF; Lohmann V
Conference publication: MOLECULAR THERAPY. 2023;31(4):358-359
Genetic Vaccine Induced T Cells Can Partially Control SARS-CoV-2 Replication
Ahlen G; Yan J; Appelberg SA; Frelin L; Mirazimi A; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2023;78:S1038
Prophylactic vaccine against hepatitis D virus (HDV) superinfection
Sallberg M; Frelin L; Ahlen G; Yan J; Maravelia P; Cunnah P; Ricardo A-R; Mertens N; Bethell R
Preprint: RESEARCH SQUARE. 2022
Novel universal SARS-CoV DNA vaccine inducing neutralizing antibodies to huCoV-19/WH01, Beta, Delta and Omicron variants and T cells to Bat-CoV
Appelberg S; Ahlen G; Nikoyan N; Yan J; Weber S; Larsson O; Höglund U; Aleman S; Weber F; Perlhamre E; Apro J; Gidlund E-K; Tuvesson O; Cadossi M; Salati S; Tegel H; Hober S; Frelin L; mirazimi A; Sallberg M
Conference publication: HEPATOLOGY. 2022;76:S333
IMMUNOTHERAPY AGAINST HBV AND HDV THAT BYPASSES IMMUNOLOGICAL DYSFUNCTION.
Frelin L; Maravelia P; Burm RJ; Ahlen G; Verhoye L; Van Houtte F; Meuleman P; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2022;77:S860
Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection
Frelin L; Maravelia P; Burm R; Ni Y; Ahlen G; Verhoye L; Van Houtte F; Pasetto A; Urban S; Meuleman P; Saellberg M
Preprint: BIORXIV. 2021
Longitudinal characterization of humoral and cellular immunity in hospitalized COVID-19 patients reveal immune persistence up to 9 months after infection
Sandberg JT; Varnaitė R; Christ W; Chen P; Muvva J; Maleki K; García M; Dzidic M; Folkesson E; Skagerberg M; Ahlén G; Frelin L; Sällberg M; The Karolinska COVID-19 Study Group; Eriksson L; Rooyackers O; Sönnerborg A; Buggert M; Björkström N; Aleman S; Strålin K; Klingström J; Ljunggren H-G; Blom K; Gredmark-Russ S
Letter: JOURNAL OF VIROLOGY. 2020;94(18):e01279-e01220
The SARS-CoV-2 N Protein Is a Good Component in a Vaccine
Ahlen G; Frelin L; Nikouyan N; Weber F; Hoglund U; Larsson O; Westman M; Tuvesson O; Gidlund E-K; Cadossi M; Appelberg S; Mirazimi A; Sallberg M
Preprint: BIORXIV. 2020
Expansion of SARS-CoV-2-specific Antibody-secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
Varnaitė R; García M; Glans H; Maleki K; Sandberg JT; Tynell J; Christ W; Lagerqvist N; Asgeirsson H; Ljunggren H-G; Ahlén G; Frelin L; Sällberg M; Blom K; Klingström J; Gredmark-Russ S
Conference publication: MOLECULAR THERAPY. 2019;27(4):139
Immunogenicity of a New Flaviviral-Based DNA Launched Suicidal Replicon for Protective Vaccination Against Hepatitis C
Johansson M; Frelin L; Maravelia P; Asghar N; Melik W; Caro-Perez N; Pasetto A; Ahlen G; Sallberg M
Conference publication: MOLECULAR THERAPY. 2019;27(4):144
Gene-Bbased Prime-Boost Immunotherapy for BockingViral Entry to Hepatocytesin Chronic Hepatitis B and D Infections
Maravelia P; Frelin L; Perez NC; Pasetto A; Ahlen G; Ni Y; Urban S; Sallberg M
Conference publication: MOLECULAR THERAPY. 2018;26(5):242
A Novel Gene Immunotherapy for Chronic HBV and HDV: Blocking Viral Entry by Neutralizing PreS1 Antibodies
Frelin L; Maravelia P; Jagya N; Verch G; Ni Y; Perez NC; Portoles I; Urban S; Saellberg M
Conference publication: JOURNAL OF VIRAL HEPATITIS. 2018;25:9-10
A novel gene immunotherapy for chronic HBV and HDV: blocking viral entry by neutralizing PreS1 antibodies
Frelin L; Maravelia P; Jagya N; Verch G; Ni Y; Perez NC; Portoles I; Urban S; Saellberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2018;68:S307
Full analysis of comorbidities in chronic hepatitis Cpatients compared with matched comparators: A nationwide population-basedregister study from 2001 to 2013
Soderholm J; Buesch K; Frelin L; Brolund A; Kovamees J; Sallberg M; Lagging M
Conference publication: HEPATOLOGY. 2017;66:508A-509A
A combined therapeutic vaccine for chronic HBV and HDV infections raising broadly cross-reactive and neutralizing antibodies and genotype specific T cells
Frelin L; Maravelia P; Jagya N; Verch G; Ni Y; Urban S; Sallberg M
Review: EXPERT REVIEW OF VACCINES. 2016;15(5):629-640
Prospects and progress of DNA vaccines for treating hepatitis B
Chen M; Jagya N; Bansal R; Frelin L; Sallberg M
Review: MEDICAL MICROBIOLOGY AND IMMUNOLOGY. 2015;204(1):131-135
Electroporation for therapeutic DNA vaccination in patients
Sallberg M; Frelin L; Ahlen G; Sallberg-Chen M
Conference publication: JOURNAL OF VIRAL HEPATITIS. 2015;22:34
A new role for CD4+CD25+regulatory T cells in promoting development of fibrosis in HCV nonstructural 3/4A transgenic mice
Bansal R; Frelin L; Sallberg M
Conference publication: HEPATOLOGY. 2015;62:695A
Evaluation of protective and therapeutic strategies against hepatitis C virus in a syngenic transplantation mouse model
Sallberg M; Levander S; Holmstom F; Ahlen G; Frelin L; Long G; Rupp D; Bartenschlager R
Conference publication: JOURNAL OF HEPATOLOGY. 2014;60(1):S138
HEPATITIS C NONSTRUCTURAL PROTEIN 3/4A DAMPENS INFLAMMATION AND CONTRIBUTES TO SLOW FIBROSIS PROGRESSION DURING CHRONIC LIVER INJURY IN MICE
Bansal R; Frelin L; Brenndorfer ED; Storm G; Prakash J; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2014;60(1):S133
EVALUATION OF A HEPATITIS C VIRUS THERAPEUTIC VACCINE CANDIDATE IN WILDTYPE- AND HCV-TRANSGENIC MICE
Holmstrom F; Sallberg M; Ahlen G; Frelin L
Conference publication: JOURNAL OF HEPATOLOGY. 2014;60(1):S127
A THERAPEUTIC VACCINE BASED ON THE HEPATITIS B CORE ANTIGEN IN COMBINATION WITH INTERLEUKIN-12 EFFECTIVELY INDUCES IMMUNE RESPONSES IN HBV-TRANSGENIC MICE
Brass A; Frelin L; Sallberg M; Ahlen G
Review: DRUG RESISTANCE UPDATES. 2013;16(3-5):60-67
Containing "The Great Houdini" of viruses: Combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C
Ahlen G; Frelin L; Brenndorfer ED; Brass A; Weiland O; Chen M; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2013;58:S451
HEPATITIS C VIRUS NON-STRUCTURAL 3/4A PROTEIN EXPRESSION PROMOTES HEPATIC FIBROGENESIS IN MICE AFTER ADMINISTRATION OF CARBON TETRACHLORIDE
Bansal R; Frelin L; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2012;56:S329
A SYNTHETIC CODON-OPTIMIZED HCV NON-STRUCTURAL 5A DNA VACCINE PRIMES POLYFUNCTIONAL CD8⁺ T CELL RESPONSES IN WILDTYPE AND NS5A-TRANSGENIC MICE
Holmstrom F; Kriegs M; Hildt E; Sallberg M; Ahlen G; Frelin L
Meeting abstract: JOURNAL OF HEPATOLOGY. 2012;56:S302
THE HCV NS3/4A-MEDIATED IMPAIRMENT OF THE HEPATIC ANTIVIRAL IMMUNE RESPONSE IS REVERSED BY PROTEASE INHIBITION OR RIBAVIRIN IN VIVO
Brenndorfer ED; Brass A; Soderholm J; Frelin L; Bode JG; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2011;54:S492-S493
HIGH CLEARANCE RATE OF VIREMIA IN PATIENTS WITH CHRONIC HEPATITIS C OF GENOTYPE 1 RECEIVING STANDARD-OF-CARE THERAPY FOLLOWING THERAPEUTIC DNA VACCINATION
Weiland O; Frelin L; Ahlen G; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2011;54:S306-S307
IN VIVO INTRACELLULAR INJECTION NEEDLE (IVIN) TECHNOLOGY: A NEW NEEDLE FOR IMPROVED CELLULAR UPTAKE OF DNA IN A LIVE ANIMAL
Ahlen G; Frelin L; Sallberg M
Meeting abstract: JOURNAL OF HEPATOLOGY. 2011;54:S476-S477
HETEROLOGOUS T CELLS CAN HELP RESTORE FUNCTION IN DYSFUNCTIONAL HEPATITIS C VIRUS SPECIFIC T CELLS DURING THERAPEUTIC VACCINATION
Frelin L; Ahlen G; Chen A; Brenndorfer ED; Brass A; Holmstrom F; Chen M; Soderholm J; Milich DR; Sallberg M
Meeting abstract: JOURNAL OF HEPATOLOGY. 2010;52:S239
IMPROVING ON THE ABILITY OF ENDOGENOUS HEPATITIS B CORE ANTIGEN TO PRIME CYTOTOXIC T LYMPHOCYTES
Chen A; Nystrom J; Frelin L; Ahlen G; Koh S; Peterson DL; Fons M; Milich D; Hultgren C; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2010;52:S265
HCV NS3/4A INTERFERES WITH INTRAHEPATIC IMMUNITY AND TNFA-INDUCED LIVER DAMAGE BY MODULATING CCL17 AND CXCL9 SECRETION IN VIVO
Brenndorfer ED; Frelin L; Soderholm J; Bode JG; Sallberg M
Conference publication: JOURNAL OF HEPATOLOGY. 2010;52:S265
HCV NS3/4A-MEDIATED CCL2 AND TNFA SECRETION INCREASE HEPATOCYTE SURVIVAL AND LIVER REGENERATION IN VIVO
Brenndorfer ED; Weiland M; Frelin L; Derk E; Ahlen G; Bode JG; Sallberg M
Review: EXPERT OPINION ON BIOLOGICAL THERAPY. 2009;9(7):805-815
DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target
Sallberg M; Frelin L; Weiland O
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S18-S19
A FIRST CLINICAL TRIAL OF THERAPEUTIC VACCINATION USING NAKED DNA DELIVERED BY IN VIVO ELECTROPORATION SHOWS ANTIVIRAL EFFECTS IN PATIENTS WITH CHRONIC HEPATITIS C
Sallberg MM; Frelin L; Diepolder H; Jung M-C; Mathiesen I; Fons M; Hultcrantz R; Carlsson T; Weiland O
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S124
THE HEPATITIS C VIRUS ENHANCES ACTIVATION OF THE EGF-RECEPTOR AND AKT-ACTIVITY BY NS3/4A-MEDIATED CLEAVAGE OF THE T-CELL PROTEIN TYROSINE PHOSPHATASE
Brenndoerfer E; Karthe J; Frelin L; Cebula P; Erhardt A; Hengel H; Bartenschlager R; Sallberg M; Haeussinger D; Bode J
Meeting abstract: JOURNAL OF HEPATOLOGY. 2009;50:S47
COMBINATION THERAPY WITH THERAPEUTIC VACCINATION AND INHIBITION OF PD-L1 IMPROVES T CELL FUNCTION IN HCV-TRANSGENIC MICE
Frelin L; Brenndorfer ED; Ahlen G; Chen A; Tjelle T; Kjeken R; Fons M; Mathiesen I; Sallberg M
Editorial comment: GENOME MEDICINE. 2009;1(1):15
A small step closer to the Holy Grail of DNA vaccines: undisputed clinical benefit in humans
Frelin L; Sallberg M
Conference publication: MOLECULAR THERAPY. 2009;17:S15
Activation of T Cell Responses and Reductions in the Viral Load Following Therapeutic Vaccination Using Naked DNA Delivered by In Vivo Electroporation in Patients with Chronic Hepatitis C
Sallberg M; Frelin L; Diepolder HM; Jung MC; Mathiesen I; Kjeken R; Fons M; Hulterantz R; Weiland O
Conference publication: MOLECULAR THERAPY. 2009;17:S368-S369
Therapeutic Vaccination Combined with Inhibition of PD-L1 Improves T Cell Function in Hepatitis C Virus-Transgenic Mice
Frelin L; Brenndorfer E; Ahlen G; Chen A; Tjelle T; Kjeken R; Fons M; Mathiesen I; Sallberg M
Conference publication: HEPATOLOGY. 2008;48(4):1022A-1023A
ANTIVIRAL EFFECTS OF THERAPEUTIC VACCINATION WITH NAKED DNA DELIVERED BY IN VIVO ELECTRO-PORTION IN PATIENTS WITH CHRONIC HEPATITIS C
Sallberg M; Diepolder HM; Jung MC; Frelin L; Mathiesen I; Fons MP; Hultcrantz RW; Carlsson T; Weiland O
Thesis / dissertation: 2004
Development of vaccines and experimental models for chronic infections caused by the hepatitis C virus
Frelin, Lars
Visa fler

Forskningsbidrag

Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies
Swedish Research Council
1 January 2020 - 31 December 2022
Pathogenesis and immune evasion strategies of hepatitis viruses: New transgenic mouse models and new therapies
Swedish Research Council
1 January 2017 - 31 December 2019
Understanding the hepatitis C virus nonstructural 5A protein: A new target for antiviral therapies
Swedish Research Council
1 January 2012 - 31 December 2014

Anställningar

Forskare, Laboratoriemedicin, Karolinska Institutet, 2011-

Examina och utbildning

Docent, Virologi, Karolinska Institutet, 2013
MEDICINE DOKTORSEXAMEN, Institutionen för laboratoriemedicin, Karolinska Institutet, 2004

Om mig

Forskningsbeskrivning

Artiklar

Alla övriga publikationer

Forskningsbidrag

Anställningar

Examina och utbildning

Nyheter från KI

Kalenderhändelser från KI